MX2021001287A - Métodos para tratar trastornos neurodegenerativos. - Google Patents

Métodos para tratar trastornos neurodegenerativos.

Info

Publication number
MX2021001287A
MX2021001287A MX2021001287A MX2021001287A MX2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A MX 2021001287 A MX2021001287 A MX 2021001287A
Authority
MX
Mexico
Prior art keywords
methods
neurodegenerative disorders
treating neurodegenerative
treating
disorders
Prior art date
Application number
MX2021001287A
Other languages
English (en)
Spanish (es)
Inventor
Petr Kocis
Martin Tolar
John Hey
Neil William Flanzraich
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of MX2021001287A publication Critical patent/MX2021001287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2021001287A 2018-08-01 2019-07-30 Métodos para tratar trastornos neurodegenerativos. MX2021001287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2021001287A true MX2021001287A (es) 2021-07-15

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001287A MX2021001287A (es) 2018-08-01 2019-07-30 Métodos para tratar trastornos neurodegenerativos.

Country Status (27)

Country Link
US (2) US12083082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829563B1 (cg-RX-API-DMAC7.html)
JP (1) JP7573512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716959B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867485A (cg-RX-API-DMAC7.html)
AU (1) AU2019315853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001739A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000269A1 (cg-RX-API-DMAC7.html)
DK (1) DK3829563T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190406A1 (cg-RX-API-DMAC7.html)
ES (1) ES3011716T3 (cg-RX-API-DMAC7.html)
FI (1) FI3829563T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250206T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070101T2 (cg-RX-API-DMAC7.html)
IL (1) IL280424B2 (cg-RX-API-DMAC7.html)
LT (1) LT3829563T (cg-RX-API-DMAC7.html)
MX (1) MX2021001287A (cg-RX-API-DMAC7.html)
MY (1) MY206530A (cg-RX-API-DMAC7.html)
PH (1) PH12021550213A1 (cg-RX-API-DMAC7.html)
PL (1) PL3829563T3 (cg-RX-API-DMAC7.html)
PT (1) PT3829563T (cg-RX-API-DMAC7.html)
RS (1) RS66516B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100767XA (cg-RX-API-DMAC7.html)
SI (1) SI3829563T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500080T1 (cg-RX-API-DMAC7.html)
UA (1) UA130011C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020028290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
SI2089417T1 (sl) * 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2014121083A1 (en) * 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.

Also Published As

Publication number Publication date
EP3829563A1 (en) 2021-06-09
US20250213507A1 (en) 2025-07-03
ES3011716T3 (en) 2025-04-08
EA202190406A1 (ru) 2021-10-15
BR112021001739A2 (pt) 2021-04-27
HUE070101T2 (hu) 2025-05-28
AU2019315853A1 (en) 2021-03-18
KR102716959B1 (ko) 2024-10-11
SMT202500080T1 (it) 2025-03-12
US12083082B2 (en) 2024-09-10
RS66516B1 (sr) 2025-03-31
LT3829563T (lt) 2025-02-25
CL2021000269A1 (es) 2021-06-18
PL3829563T3 (pl) 2025-04-07
IL280424B2 (en) 2025-01-01
SI3829563T1 (sl) 2025-05-30
MY206530A (en) 2024-12-19
SG11202100767XA (en) 2021-02-25
AU2019315853B2 (en) 2025-05-01
JP2021533128A (ja) 2021-12-02
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
CN112867485A (zh) 2021-05-28
IL280424B1 (en) 2024-09-01
KR20210039415A (ko) 2021-04-09
US20210315847A1 (en) 2021-10-14
PH12021550213A1 (en) 2021-11-03
FI3829563T3 (fi) 2025-02-17
CA3108150A1 (en) 2020-02-06
WO2020028290A1 (en) 2020-02-06
PT3829563T (pt) 2025-02-18
HRP20250206T1 (hr) 2025-04-11
DK3829563T3 (en) 2025-02-24
JP7573512B2 (ja) 2024-10-25
IL280424A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
DOP2018000242A (es) Moduladores del camino de estrés integrado
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
MX2020010469A (es) Inhibidores del atf6 y sus usos.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
MX2019002606A (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
BR112018010216A2 (pt) purinonas como inibidores da protease específica da ubiquitina 1
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
CR20200214A (es) ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
MX375372B (es) COMPOSICIONES DE COMPUESTOS DE MOLÉCULA PEQUEÑA Y USO DE LOS MISMOS COMO INHIBIDORES TrKA.
IL263433A (en) Methods for treating alzheimer&#39;s disease
EP3487507A4 (en) VIRAL VECTORS FOR TREATING PARKINSON&#39;S DISEASE
EA201990400A1 (ru) Соединения и композиции и их применение
CL2021000269A1 (es) Métodos para tratar trastornos neurodegenerativos
MX378940B (es) Trastornos neurodegenerativos.
DK3463351T3 (da) Behandling til parkinsons sygdom
MX377304B (es) Derivados de piperazina como moduladores de los receptores x del hígado.
MX378739B (es) Compuestos de 2-oxindol.
MA46353A (fr) Méthodes de traitement de l&#39;infertilité féminine
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
EP3887514A4 (en) THERAPEUTIC GENERATE EDITING FOR ELAN-ASSOCIATED DISEASE
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
CY1124821T1 (el) Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ